Karas Eric 4
4 · ARS Pharmaceuticals, Inc. · Filed Dec 4, 2024
Insider Transaction Report
Form 4
Karas Eric
Chief Commercial Officer
Transactions
- Exercise/Conversion
Stock Option (Right to Buy)
2024-12-02−3,717→ 590,871 totalExercise: $1.50Exp: 2032-05-23→ Common Stock (3,717 underlying) - Exercise/Conversion
Common Stock
2024-12-04$1.50/sh+6,283$9,425→ 11,976 total - Exercise/Conversion
Common Stock
2024-12-02$1.50/sh+3,717$5,576→ 9,410 total - Sale
Common Stock
2024-12-02$14.11/sh−3,717$52,461→ 5,693 total - Sale
Common Stock
2024-12-04$14.00/sh−6,283$87,962→ 5,693 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-12-04−6,283→ 584,588 totalExercise: $1.50Exp: 2032-05-23→ Common Stock (6,283 underlying)
Footnotes (3)
- [F1]The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 26, 2024.
- [F2]The weighted average sale price for the transaction reported was $14.1139, and the range of prices were between $14.00 and $14.35. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- [F3]Immediately exercisable.